Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]BIBD-181
- Development stage
- Unknown
- Lead developer
- Capital Medical University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
01
Overview
[18F]BIBD-181: sourced facts only. name: "Autoradiography and PET inhibition studies indicated that [18F]BIBD-181 specifically binds SV2A." [PMID:35450380]; target: "Autoradiography and PET inhibition studies indicated that [18F]BIBD-181 specifically binds SV2A." [PMID:35450380]; developer: "Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China." [PMID:35450380]; modality: "Herein we report the synthesis of the novel radiotracer [18F]BIBD-181 and its preclinical evaluation." [PMID:35450380]
Beyond the preview
Go deeper on [18F]BIBD-181.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]BIBD-181.